1 2 3	Elevated fecal mitochondrial DNA from symptomatic norovirus infections suggests potential health relevance of human mitochondrial DNA in fecal source tracking
5 4 5 6	Kevin J. Zhu, Brittany Suttner, Jackie Knee, Drew Capone, Christine L. Moe, Christine E. Stauber, Kostas T. Konstantinidis, Thomas E. Wallach, Amy J. Pickering, Joe Brown
0 7 8	Corresponding Author
9 10 11	Joe Brown – Department of Environmental Sciences and Engineering, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States
12 13 14	Author Information
14 15 16 17	Kevin J. Zhu – School of Civil and Environmental Engineering, Georgia Institute of Technology, Atlanta, Georgia 30332, United States
17 18 19 20	Brittany Suttner – School of Civil and Environmental Engineering, Georgia Institute of Technology, Atlanta, Georgia 30332, United States
20 21 22 23	Jackie Knee – Department of Disease Control, London School of Hygiene and Tropical Medicine, London, United Kingdom
24 25 26 27	Drew Capone – Department of Environmental Sciences and Engineering, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States
27 28 29 30	Christine L. Moe – Center for Global Safe Water, Sanitation, and Hygiene, Rollins School of Public Health, Emory University, Atlanta, Georgia 30322, United States
31 32 33	Christine E. Stauber – Department of Population Health Sciences, School of Public Health, Georgia State University, Atlanta, Georgia 30302, United States
34 35 36	Kostas T. Konstantinidis – School of Civil and Environmental Engineering, Georgia Institute of Technology, Atlanta, GA 30332, United States
37 38 39	Thomas E. Wallach – Division of Pediatric Gastroenterology, SUNY Downstate Health Sciences University, Brooklyn, New York 11203, United States
40 41	Amy J. Pickering – Department of Civil and Environmental Engineering, University of California, Berkeley, California 94720, United States

42 Abstract

43 An end goal of fecal source tracking (FST) is to provide information on risk of transmission of 44 waterborne illnesses associated with fecal contamination. Ideally, concentrations of FST markers 45 in ambient waters would reflect exposure risk. Human mtDNA is an FST marker that is exclusively 46 human in origin and may be elevated in feces of individuals experiencing gastrointestinal 47 inflammation. In this study, we examined whether human mtDNA is elevated in fecal samples 48 from individuals with symptomatic norovirus infections using samples from the US, Mozambique, 49 and Bangladesh. We quantified hCYTB484 (human mtDNA) and HF183/BacR287 (humanassociated Bacteroides) FST markers using droplet digital PCR. We observed the greatest 50 51 difference in concentrations of hCYTB484 when comparing samples from individuals with 52 symptomatic norovirus infections versus individuals without norovirus infections or diarrhea 53 symptoms: \log_{10} increase of 1.42 in US samples (3,820% increase, p-value = 0.062), 0.49 in 54 Mozambique (308% increase, p-value = 0.061), and 0.86 in Bangladesh (648% increase, p-value 55 = 0.035). We did not observe any trends in concentrations of HF183/BacR287 in the same samples. 56 These results suggest concentrations of fecal mtDNA increase during symptomatic norovirus 57 infection and that mtDNA in environmental samples may represent an unambiguously human 58 source-tracking marker that correlates with enteric pathogen exposure risk.

59 Introduction

60 Fecal source tracking (FST) aims to detect fecal contamination in environmental samples and identify the source using a variety of chemical and biological methods. Method validation studies 61 62 to date have demonstrated FST markers targeting human-associated microbial DNA to have 63 variable sensitivity (true positive rate) and specificity (true negative rate) across geographies 1-5. 64 Human mitochondrial DNA (mtDNA) markers, having been demonstrated to have high sensitivity $^{6-9}$ and high specificity $^{6-9}$ across varying geographies, may complement the use of microbial FST 65 66 targets, especially in settings or environmental matrices where other FST markers have not been previously validated ⁹. 67

68

69 In addition to retaining high sensitivity and specificity, an ideal FST marker would also convey 70 information about the risk associated with detected fecal contamination: increasing concentration 71 of FST markers in environmental samples should indicate increasing risk of gastrointestinal and other waterborne illnesses associated with exposure ¹⁰. This increasing risk may be due to an 72 73 increase in fecal input generally increasing chances of pathogens being present or due to a fecal 74 source present with particularly high concentrations of infectious pathogens. However, such a 75 marker has not yet been identified. mtDNA FST markers differ from microbial markers because 76 they target host DNA instead of host-associated microbial DNA. The main cellular sources of fecal mtDNA are thought to be intestinal epithelial cells (IEC) 6,7 and white blood cells (leukocytes) 6,11 . 77 78 IECs constitute the intestinal epithelium that prevents the entry of harmful substances into the body 79 while selectively allowing entry of beneficial nutrients. Leukocytes transmigrate into the intestinal 80 lumen during enteric infections. Because of these origins, fecal mtDNA concentrations may 81 exhibit baseline levels during homeostasis (e.g., IEC shedding to balance IEC proliferation) with

elevated levels during inflammatory events (e.g., infection triggering leukocyte transmigration,
increased apoptosis, IEC extrusion and shedding) ^{12,13}.

84

A key assumption often used when assessing risk associated with fecal indicators is that 85 86 concentrations of fecal indicators covary with concentrations of sewage present and, therefore, 87 concentrations of pathogens. If concentrations of mtDNA FST markers increase during cases of 88 enteric infections, specifically in symptomatic cases where vomiting and/or diarrhea facilitates the 89 shedding of pathogens, mtDNA markers may advance the capabilities of FST markers by 90 providing risk information beyond the assumed covariance between concentrations of indicator 91 and pathogen. Associations between mtDNA FST markers and enteric infections have not yet been 92 studied, and it is unknown whether concentrations of fecal mtDNA are indicative of symptomatic 93 enteric infections.

94

95 The aim of this study was to investigate whether concentrations of a human mtDNA FST marker 96 are higher in feces from individuals with symptomatic norovirus infections than feces from 97 individuals without. We used archived fecal samples from participants in studies conducted in the 98 US, Mozambique, and Bangladesh, and compared fecal mtDNA concentrations across three 99 groups: (1) no detected enteric infection and no diarrhea, (2) norovirus infection and no diarrhea, 100 and (3) norovirus infection and diarrhea. We hypothesized that concentrations of fecal mtDNA 101 will be highest in feces from symptomatic norovirus infections versus those from individuals with 102 asymptomatic norovirus infections or no enteric infections.

103

104 Materials and Methods

105 Feces Samples. We obtained human fecal samples from three different studies conducted in the 106 US, Mozambique, and Bangladesh. We first investigated the US samples, using pairs of one pre-107 and one post-challenge sample per subject from a norovirus Genogroup I (GI) challenge study in 108 which norovirus-spiked ovsters were used as the intentional exposure ¹⁴. These pre- and post-109 challenge pairs were from six subjects who developed asymptomatic norovirus infections and five 110 subjects who developed symptomatic norovirus infections (Table 1). In the challenge study, 111 symptoms (chills, cramping, diarrhea, fatigue, fever, headache, myalgia, nausea, vomiting, white 112 blood cell shift) were recorded during the challenge period and follow-up visits ¹⁴. To be classified 113 as symptomatic, a subject had to have at least one of the above symptoms, with fever requiring at 114 least one other associated symptom.

115

116 Following initial results from the US samples (Figure S1), we expanded the analysis to include 117 archived fecal samples from two other studies: 1) a cross-sectional study of child (under four years of age) enteric infections in urban Maputo, Mozambique ^{15,16} and 2) an experimental trial 118 119 evaluating the effect of passive chlorination devices at shared water points on child (under five years of age) diarrhea prevalence in urban Bangladesh^{17,18}. We classified the fecal samples using 120 121 the following criteria: 1) no enteric pathogens detected and from individuals with no reported 122 diarrhea (hereafter referred to as enteric-asymptomatic), 2) norovirus GI/GII detected and from 123 individuals with no reported diarrhea (noro⁺asymptomatic), 3) norovirus GI/GII detected, and from 124 individuals with reported diarrhea (noro⁺symptomatic). Detection of enteric pathogens in the archived Mozambique and Bangladesh samples was determined by the Luminex (Austin, Texas, 125 US) xTAG® Gastrointestinal Pathogen Panel RUO (GPP) in previous studies ^{15,18}. The GPP 126 127 detects the nucleic acid markers of 15 bacterial, viral, and parasitic enteric pathogens, including

norovirus GI/GII with a limit of detection for norovirus GI/GII on the order of 10⁶ genome 128 129 copies/gram of feces ¹⁹. There were low numbers of norovirus-positive feces in the Mozambique 130 and Bangladesh samples, and feces positive for norovirus were often positive for another GPP target ^{15,18}. Because of this, we included norovirus-positive feces that were positive for additional 131 132 pathogen(s) in the noro+asymptomatic and noro+symptomatic groups. We identified 133 enteric⁻asymptomatic samples by selecting feces that were negative for all Luminex GPP targets. 134 Reported diarrhea in the Bangladesh and Mozambique studies was based on caregiver-reported 135 diarrhea criteria of \geq 3 loose or watery feces in a 24-hr period with a 1-week recall period. Because the Bangladesh ¹⁷ and Mozambique ¹⁵ studies observed low prevalence of caregiver-reported 136 137 diarrhea, we were limited in the number of noro⁺symptomatic samples we could examine (Table 138 1).

139

140 DNA Extraction and ddPCR. Prior to DNA extraction, we stored fecal samples at -80°C. For US 141 samples, we performed DNA extractions using 0.1 g of fecal sample and the MO BIO PowerSoil® 142 kit (Carlsbad, CA, USA) following manufacturer's instructions. For Mozambique and Bangladesh 143 samples, we performed DNA extractions using 0.1 g of fecal sample and the Qiagen QIA amp® 144 96 PowerFecal QIAcube® HT Kit automated on the Qiagen QIAcube® HT platform (Hilden, 145 Germany) following manufacturer's instructions, using soil grinding SK38 bead tubes (Bertin 146 Corp., Rockville, MD, USA) containing 650 µl pre-warmed Buffer PW1 and homogenizing the 147 bead tubes on a vortexer for 10 minutes. Following DNA extraction, we stored all extracts at -80°C until analysis. We quantified hCYTB484⁹ and HF183/BacR287²⁰ markers through droplet 148 digital PCR (ddPCR) on Bio-Rad QX200[™] Droplet Digital[™] PCR (Hercules, CA, USA) using 149 methods developed previously ⁹ and normalized marker concentrations to nanograms of double 150

151 stranded DNA (ng dsDNA) as measured by Qubit 3.0 Fluorometer with Qubit High Sensitivity 152 DNA kits (ThermoFisher Scientific, Waltham, MA, USA) to account for differences in moisture content between feces and any potential differential recovery between kits²¹. Results of biological 153 154 replicates for a subset of samples are in supporting information (Table S1). Minimum Information for Publication of Quantitative Digital PCR Experiments²² is included in the supporting 155 156 information (Table S2). For both assays, we classified samples as not detected if amplification was 157 below our analytical limit of detection of three positive partitions per ddPCR well⁹. For the 158 analytical lower limit of quantification, we used previously established assay-specific limits⁹.

159

160 **Data Analysis.** Because the US samples were collected pre- and post-challenge from each subject, 161 we applied the Wilcoxon signed rank paired test. For the Mozambique and Bangladesh sample 162 sets (cross-sectional data), we used the Kruskal-Wallis test, followed with the Dunn test with 163 Benjamini-Hochberg adjustment. We calculated effect sizes for log₁₀ transformed concentrations 164 through a difference in means approach using Cohen's d, the difference between the two means 165 divided by the pooled standard deviation. To compare the relative influences of potential 166 confounders, we fitted a generalized linear model (GLM) using a Gaussian identity function to the 167 Mozambique and Bangladesh sample sets using reported diarrhea and norovirus GI/GII 168 detected/not detected (as determined by the GPP) as the independent variables and \log_{10} values of 169 hCYTB484 normalized to ng of dsDNA as the dependent variable while adjusting for number of 170 pathogens detected (as determined by the GPP), sex, age (continuous, number of months), and 171 study population (Mozambique or Bangladesh). More information on model fitting can be found 172 in the supporting information. We performed data analyses in R version 4.0.1.

173

174 **Results and Discussion**

175 We detected hCYTB484 above quantifiable levels in 100% of the samples in this study and found 176 increases in hCYTB484 in samples from symptomatic norovirus infections. We observed the 177 largest differences in median hCYTB484 copies / ng dsDNA between the enteric-asymptomatic 178 and noro⁺symptomatic groups (Figure 1, Table 2): a log₁₀ increase of 1.42 for US samples (3,820% 179 increase, p-value of 0.062, effect size = 4.3), 0.49 increase for Mozambique samples (308%) 180 increase, p-value of 0.061, effect size = 0.70), and 0.86 increase for Bangladesh samples (648%) 181 increase, p-value of 0.035, statistically significant at $\alpha = 0.05$ level, effect size = 1.5). The larger 182 effect sizes between enteric-asymptomatic and noro+symptomatic versus enteric-asymptomatic 183 and noro⁺asymptomatic across all three countries (Table 2) suggest that fecal mtDNA 184 concentrations are higher in symptomatic norovirus infections than in asymptomatic norovirus 185 infections (effect sizes calculated as the difference between means normalized to the pooled 186 standard deviation). To investigate what variables influenced fecal mtDNA concentrations, we 187 standardized the GLM regression coefficients to account for different units of measurements and 188 variances of each variable. The standardized GLM regression coefficients (Table S3) show reported diarrhea (0.16, 95% CI: 0 – 0.32, p-value = 0.045), norovirus detected (0.12, 95% CI: -189 190 0.16 - 0.39, p-value = 0.38), age in months (-0.12, 95% CI: -0.28 - 0.03, p-value = 0.12), and 191 study population (Bangladesh or Mozambique) (0.19, 95% CI: -0.36 - -0.03, p-value = 0.018) as 192 having the largest magnitudes. However, only reported diarrhea and study population had p-values 193 < 0.05 (0.045 and 0.018, respectively). Comparison of the standardized regression coefficients 194 after adjusting for other potential biological confounders suggest that, of the variables tested, 195 diarrhea and study population had the largest influences on fecal mtDNA concentrations.

196

197 The largest increase in concentrations of fecal mtDNA occurred in the US samples, for several possible reasons. Firstly, epithelial cell proliferation declines with age ²³. Compared to the adults 198 199 in the US study, the children in the Mozambique and Bangladesh studies may have had higher 200 levels of proliferation even when not experiencing diarrhea. Secondly, fecal mtDNA 201 concentrations may have varied due to environmental enteric dysfunction (EED)²⁴. The 202 Mozambique and Bangladesh study settings had high prevalence of enteric pathogen exposure ^{15,18} 203 as measured by frequency of pathogen detection in feces ²⁵: estimated 86% and 88% of feces 204 containing one or more pathogens in Mozambique and Bangladesh samples, respectively. EED, a condition caused by persistent exposure to enteric pathogens, infections, or perturbations and 205 206 characterized by deleterious changes in the intestinal epithelium, can result in malabsorption and 207 diminished growth and development in children. Despite deleterious changes associated with EED 208 that may potentially change fecal mtDNA concentrations, such as reduced intestinal villi, EED 209 typically presents with few or no acute symptoms, potentially reducing in the effect size we 210 observed in samples from Mozambique and Bangladesh. Lastly, the method of reporting diarrhea 211 differed between the US versus Mozambique and Bangladesh samples: clinical monitoring versus caregiver reported. Caregiver-reported diarrhea is subject to recall biases ^{26,27}, which may have 212 213 resulted in misclassification of samples.

214

We did not observe any increases in HF183/BacR287 marker copies / ng dsDNA between the enteric⁻asymptomatic and noro⁺symptomatic groups (Figure 1), indicating that the elevated mtDNA concentrations may be specific to mtDNA and not due to a bulk increase in fecal markers. Furthermore, we detected the HF183/BacR287 marker in 52% of samples, with only 31% of samples above the analytical lower limit of quantification (quantifiable), a finding consistent with

assessments of HF183 in individual human feces across the globe ^{5,28}. In contrast, we quantified 100% of samples in this study for hCYTB484. HF183/BacR287 was quantifiable in less than a third of the samples and did not exhibit any consistent pattern between the enteric⁻asymptomatic and noro⁺symptomatic groups, suggesting that HF183/BacR287 is not widely quantifiable across individual humans nor are levels of HF183/BacR287 concentration indicative of changes in intestinal inflammatory status. For these reasons, these results suggest HF183/BacR287 would be less useful as a biomarker of intestinal inflammation.

227

228 A variety of sources and processes related to the health of the gastrointestinal system influence 229 fecal mtDNA concentrations. Because the integrity of the intestinal epithelium is essential to the 230 host's health, IECs proliferate and are removed in a highly active and regulated cycle²⁹. IEC 231 removal likely depends on the epithelium and host's health, including various potential mechanisms: engulfment following apoptosis ^{30,31}, shedding into the intestinal lumen ^{32–35}, 232 shedding in response to pathogen or pathogen-associated insults ^{36–38}, and shedding during other 233 pathological states such as inflammatory bowel disease, neoplastic growth ³⁹, and wound healing 234 235 ³⁴. Additionally, current evidence of norovirus infection in humans points towards enterocytes in the small intestines as the primary tropism ^{40,41}. Noroviruses, as non-enveloped viruses, are 236 237 presumed to have lytic effects on their host cells ⁴², potentially releasing host mtDNA into the 238 intestinal lumen. Leukocytes can be found in feces from individuals with inflammatory diarrhea ^{40,43,44}, and neutrophils are highly abundant first responders, transmigrating across the intestinal 239 epithelium during enteric infections ⁴⁵. Lastly, there is emerging evidence of mtDNA's immune-240 signaling role in inflammatory diseases: pathogen-associated signal ⁴⁶ and damage-associated 241 molecular pattern ^{13,47}. Many of these processes through which mtDNA is shed in feces are 242

involved with gastrointestinal health, lending plausibility to our observation of increased fecal
mtDNA during symptomatic norovirus infections. However, non-pathogenic diseases such as
inflammatory bowel disease and neoplastic growth may also cause elevated fecal mtDNA.

246

Several limitations qualify our results. Prevalences of reported diarrhea in the Bangladesh¹⁷ and 247 Mozambique ¹⁵ trials were low, limiting the number of samples in our analysis and constraining 248 249 statistical power. Reported diarrhea in these studies was assessed through a caregiver survey and is subject to observational and recall biases ^{26,27}. Multiple pathogens were commonly detected in 250 251 the Bangladesh and Mozambique fecal samples, with norovirus rarely detected alone. Co-252 infections may have affected fecal mtDNA concentrations as well as symptomology; norovirus 253 may not have always been the cause of symptoms. While norovirus is an important cause of 254 gastroenteritis globally, there are other enteric pathogens that can be transmitted through exposure 255 to fecal contamination in the environment and are relevant to FST.

256

257 A human-specific FST marker that is informative of risk of illness is needed because fecal indicator 258 bacteria exhibit non-specificity in the environment (cross-reactivity and regrowth) and because human fecal contamination represents an important risk to human health $^{48-52}$. In this study, we 259 260 observed increased concentrations of mtDNA in feces from individuals with symptomatic 261 norovirus infections when compared to feces from individuals without norovirus infections or diarrhea symptoms. This suggests that mtDNA markers may serve as biomarkers of intestinal 262 263 inflammation and may provide risk-relevant information by increasing in concentration when an individual is at higher risk of transmitting norovirus infection ⁵³. However, more work needs to be 264 done to understand current limitations of human mtDNA in FST ⁹. We need better understanding 265

266 of the cellular sources of fecal mtDNA, intactness of fecal mtDNA after defecation, and what 267 conditions modulate fecal mtDNA concentrations. Approaches investigating processes relevant to 268 gastrointestinal health (e.g., expression of IEC proliferation genes) could also help identify 269 relevant mechanisms that modulate fecal mtDNA. Studies on the fate and persistence of fecal 270 mtDNA^{8,55} are needed to understand how the signal is attenuated in environments relative to that of infectious pathogens ^{56,57}. Before human mtDNA, a nucleic acid marker, can serve as a risk-271 relevant FST marker, we need to understand its relationship with infectious pathogens ⁵⁴. Because 272 273 human mtDNA FST markers are typically found at lower concentrations in sewage than those of 274 other human-associated FST markers, improved concentration and recovery methods of mtDNA 275 are needed ^{10,58-61}. Better understanding of potential non-fecal sources of mtDNA and at what 276 concentrations non-fecal sources shed mtDNA are also needed ⁶². Potential carry over from consumption of meat or feces of other species should also be investigated ^{6,9}. Despite these 277 278 knowledge and technical gaps, results from this study add to previous evidence supporting the 279 utility of human mtDNA as FST markers.

280

281 Acknowledgements

This material is based upon work supported by the National Science Foundation under Grant Number 1511825 and the United States Geological Survey under Project ID 2018GA388B. We received further support from the Bill and Melinda Gates Foundation grant OPP1137224 and the World Bank Strategic Impact Evaluation Fund (SIEF). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We acknowledge Janet Hatt, Minjae Kim, Angela Peña-Gonzalez, Trent Sumner, Sid Patel, and Victoria Dean.

289 Tables

Study population	Individuals from which samples were collected	Ages of individuals	enteric⁻asymptomatic	noro*asymptomatic	noro*symptomatic
US ^a	11	Adult (18 to 50 years of age)	11	6	5
Mozambique	66	Children (< 4 years of age)	26	29	11
Bangladesh	120	Children (< 5 years of age)	49	68	3

290 Table 1. Sample frame for this study.

291

^a All US samples were part of paired samples (pre-challenge and post-challenge) from 11 292 individuals. 6 individuals did not develop symptoms; 5 individuals did develop symptoms.

293

294 **Table 2.** Comparison of log₁₀ human mtDNA copies normalized to ng of dsDNA amongst the 295 different health status groups.

	Kruskal- Wallis test	enteric ⁻ as versus noro	ymptom †asympto	atic omatic	noro*asymj noro*sy	noro ⁺ asymptomatic versus noro ⁺ symptomatic			enteric⁻asymptomatic versus noro⁺symptomatic			
Sample Set	<i>p</i> -value	log10 increase in mean hCYTB484 copies / ng dsDNA	<i>p</i> - value	effect size ^c	log ₁₀ increase in mean hCYTB484 copies / ng dsDNA	<i>p-</i> value	effect size ^c	log ₁₀ increase in mean <i>p</i> - hCYTB484 value copies / ng dsDNA		effect size ^c		
US	N/A	0.25 (168 %)	1 ^b	0.60	N/A	N/A	N/A	1.42 (3,820 %)	0.062 ^b	4.3		
Mozambique	0.068	0.22 (138 %)	0.36ª	0.32	0.27 (223 %)	0.15ª	0.39	0.49 (308 %)	0.061ª	0.70		
Bangladesh	0.024	0.16 (111 %)	0.14ª	0.27	0.70 (585 %)	0.057ª	1.2	0.86 (648%)	0.035 ^{a*}	1.5		

296 * Statistically significant result at the $\alpha = 0.05$ level

297 ^a Dunn test adjusted with the Benjamini-Hochberg method for multiple comparisons

298 ^b Wilcoxon signed rank paired test for paired pre- and post-challenge samples for each individual

299 ^c Effect size reported as the difference between the two sample means divided by the pooled

300 standard deviation of the log_{10} transformed data (Cohen's *d*). The larger the effect size, the larger

301 the difference between the mean of the two sample distributions.

302

303 Figures

304



305

306 Figure 1. Box and whisker plots of hCYTB484 (top plot) and HF183/BacR287 (bottom plot) 307 concentrations for the various health statuses in this study. Horizontal lines (box) denote the 25th, 50th, and 75th percentiles and the end of the vertical lines (whiskers) denote the maximum or 308 309 minimum value of the data that is within 1.5 times the interquartile range over the 75th percentile or under the 25th percentile. All concentrations are plotted as log_{10} (concentration + 1) and 310 concentrations from feces are normalized to concentration of dsDNA (ng of dsDNA determined 311 312 by Qubit). The number of quantifiable samples is shown at x-axis tick mark of each box and 313 whisker ("n = #"). HF183/BacR287 plots have different numbers of quantifiable samples because HF183/BacR287 was detected in only 52% of all samples and quantifiable in 31% of all samples. 314 315

316 **References**

317

- 318 (1) Boehm, A. B.; Van De Werfhorst, L. C.; Griffith, J. F.; Holden, P. A.; Jay, J. A.; Shanks,
- 319 O. C.; Wang, D.; Weisberg, S. B. Performance of Forty-One Microbial Source Tracking
- 320 Methods: A Twenty-Seven Lab Evaluation Study. Water Research 2013, 47 (18), 6812–
- 321 6828. https://doi.org/10.1016/j.watres.2012.12.046.
- 322 (2) Harris, A. R.; Pickering, A. J.; Harris, M.; Doza, S.; Islam, M. S.; Unicomb, L.; Luby, S.;
- 323 Davis, J.; Boehm, A. B. Ruminants Contribute Fecal Contamination to the Urban
- 324 Household Environment in Dhaka, Bangladesh. *Environmental Science and Technology*

325 **2016**, *50* (9), 4642–4649. https://doi.org/10.1021/acs.est.5b06282.

- 326 (3) Nshimyimana, J. P.; Cruz, M. C.; Thompson, R. J.; Wuertz, S. Bacteroidales Markers for
 327 Microbial Source Tracking in Southeast Asia. *Water Research* 2017, *118*, 239–248.
 328 https://doi.org/10.1016/j.watres.2017.04.027.
- 329 (4) Odagiri, M.; Schriewer, A.; Hanley, K.; Wuertz, S.; Misra, P. R.; Panigrahi, P.; Jenkins,
- 330 M. W. Validation of Bacteroidales Quantitative PCR Assays Targeting Human and
- 331 Animal Fecal Contamination in the Public and Domestic Domains in India. *Science of The*
- 332 *Total Environment* **2015**, *502*, 462–470. https://doi.org/10.1016/j.scitotenv.2014.09.040.
- 333 (5) Reischer, G. H.; Ebdon, J. E.; Bauer, J. M.; Schuster, N.; Ahmed, W.; Åström, J.; Blanch,
- A. R.; Blöschl, G.; Byamukama, D.; Coakley, T.; Ferguson, C.; Goshu, G.; Ko, G.; de
- 335 Roda Husman, A. M.; Mushi, D.; Poma, R.; Pradhan, B.; Rajal, V.; Schade, M. A.;
- 336 Sommer, R.; Taylor, H.; Toth, E. M.; Vrajmasu, V.; Wuertz, S.; Mach, R. L.; Farnleitner,
- A. H. Performance Characteristics of QPCR Assays Targeting Human- and Ruminant-
- 338 Associated Bacteroidetes for Microbial Source Tracking across Sixteen Countries on Six

- 339 Continents. *Environmental Science & Technology* **2013**, *47* (15), 8548–8556.
- 340 https://doi.org/10.1021/es304367t.
- 341 (6) Caldwell, J. M.; Raley, M. E.; Levine, J. F. Mitochondrial Multiplex Real-Time PCR as a
- 342 Source Tracking Method in Fecal-Contaminated Effluents. *Environmental Science* &
- 343 *Technology* **2007**, *41* (9), 3277–3283. https://doi.org/10.1021/es062912s.
- 344 (7) Schill, W. B.; Mathes, M. V. Real-Time PCR Detection and Quantification of Nine
- 345 Potential Sources of Fecal Contamination by Analysis of Mitochondrial Cytochrome b
- 346 Targets. *Environmental Science and Technology* **2008**, *42* (14), 5229–5234.
- 347 https://doi.org/10.1021/es800051z.
- 348 (8) He, X.; Liu, P.; Zheng, G.; Chen, H.; Shi, W.; Cui, Y.; Ren, H.; Zhang, X.-X. Evaluation
- 349 of Five Microbial and Four Mitochondrial DNA Markers for Tracking Human and Pig
- 350 Fecal Pollution in Freshwater. *Scientific Reports* **2016**, *6* (1), 35311.
- 351 https://doi.org/10.1038/srep35311.
- 352 (9) Zhu, K.; Suttner, B.; Pickering, A.; Konstantinidis, K. T.; Brown, J. A Novel Droplet
- 353 Digital PCR Human MtDNA Assay for Fecal Source Tracking. *Water Research* 2020,
- 354 *183*, 116085. https://doi.org/10.1016/j.watres.2020.116085.
- 355 (10) Microbial Source Tracking: Methods, Applications, and Case Studies; Hagedorn, C.,
- Blanch, A. R., Harwood, V. J., Eds.; Springer New York: New York, NY, 2011.
- 357 https://doi.org/10.1007/978-1-4419-9386-1.
- 358 (11) Martellini, A.; Payment, P.; Villemur, R. Use of Eukaryotic Mitochondrial DNA to
- 359 Differentiate Human, Bovine, Porcine and Ovine Sources in Fecally Contaminated
- 360 Surface Water. *Water Research* **2005**, *39* (4), 541–548.
- 361 https://doi.org/10.1016/j.watres.2004.11.012.

362	(12)	Peña-Gonzalez	A.:	: Soto-Girón	M. J.:	: Smith.	S.	: Sistrunk.	J.	: Montero.	L.:	Páez.	. M.:
	(- - /		,	,	,	, ~	$\sim \cdot \cdot$,	,	,	,	,	,,

- 363 Ortega, E.; Hatt, J. K.; Cevallos, W.; Trueba, G.; Levy, K.; Konstantinidis, K. T.
- 364 Metagenomic Signatures of Gut Infections Caused by Different Escherichia Coli
- 365 Pathotypes. *Applied and Environmental Microbiology* **2019**, 85 (24), 1–18.
- 366 https://doi.org/10.1128/AEM.01820-19.
- 367 (13) Boyapati, R. K.; Dorward, D. A.; Tamborska, A.; Kalla, R.; Ventham, N. T.; Doherty, M.
- 368 K.; Whitfield, P. D.; Gray, M.; Loane, J.; Rossi, A. G.; Satsangi, J.; Ho, G. Mitochondrial
- 369 DNA Is a Pro-Inflammatory Damage-Associated Molecular Pattern Released During
- 370 Active IBD. Inflammatory Bowel Diseases 2018, 24 (10), 2113–2122.
- 371 https://doi.org/10.1093/ibd/izy095.
- 372 (14) Leon, J. S.; Kingsley, D. H.; Montes, J. S.; Richards, G. P.; Lyon, G. M.; Abdulhafid, G.
- 373 M.; Seitz, S. R.; Fernandez, M. L.; Teunis, P. F.; Flick, G. J.; Moe, C. L. Randomized,
- 374 Double-Blinded Clinical Trial for Human Norovirus Inactivation in Oysters by High
- 375 Hydrostatic Pressure Processing. *Applied and Environmental Microbiology* **2011**, 77 (15),
- 376 5476–5482. https://doi.org/10.1128/AEM.02801-10.
- 377 (15) Knee, J.; Sumner, T.; Adriano, Z.; Berendes, D.; de Bruijn, E.; Schmidt, W. P.; Nalá, R.;
- 378 Cumming, O.; Brown, J. Risk Factors for Childhood Enteric Infection in Urban Maputo,
- 379 Mozambique: A Cross-Sectional Study. *PLoS Neglected Tropical Diseases* **2018**, *12* (11),
- 380 1–19. https://doi.org/10.1371/journal.pntd.0006956.
- 381 (16) Brown, J.; Cumming, O.; Bartram, J.; Cairncross, S.; Ensink, J.; Holcomb, D.; Knee, J.;
- 382 Kolsky, P.; Liang, K.; Liang, S.; Nala, R.; Norman, G.; Rheingans, R.; Stewart, J.; Zavale,
- 383 O.; Zuin, V.; Schmidt, W.-P. A Controlled, before-and-after Trial of an Urban Sanitation
- 384 Intervention to Reduce Enteric Infections in Children: Research Protocol for the Maputo

- 385 Sanitation (MapSan) Study, Mozambique. *BMJ Open* **2015**, *5* (6), e008215–e008215.
- 386 https://doi.org/10.1136/bmjopen-2015-008215.
- 387 (17) Pickering, A. J.; Crider, Y.; Sultana, S.; Swarthout, J.; Goddard, F. G.; Anjerul Islam, S.;
- 388 Sen, S.; Ayyagari, R.; Luby, S. P. Effect of In-Line Drinking Water Chlorination at the
- 389 Point of Collection on Child Diarrhoea in Urban Bangladesh: A Double-Blind, Cluster-
- 390 Randomised Controlled Trial. *The Lancet Global Health* **2019**, 7 (9), e1247–e1256.
- 391 https://doi.org/10.1016/S2214-109X(19)30315-8.
- 392 (18) Berendes, D.; Capone, D.; Knee, J.; Holcomb, D.; Sultana, S.; Pickering, A. J.; Brown, J.
- 393 Associations between Enteric Pathogen Carriage and Height-for-Age, Weight-for-Age and
- Weight-for-Height in Children under 5 Years Old in Urban Dhaka, Bangladesh.
- 395 *Epidemiology and Infection* **2020**, *148*, e39. https://doi.org/10.1017/S0950268820000369.
- 396 (19) Navidad, J. F.; Griswold, D. J.; Gradus, M. S.; Bhattacharyya, S. Evaluation of Luminex
- 397 XTAG Gastrointestinal Pathogen Analyte-Specific Reagents for High-Throughput,
- 398 Simultaneous Detection of Bacteria, Viruses, and Parasites of Clinical and Public Health
- 399 Importance. *Journal of Clinical Microbiology* **2013**, *51* (9), 3018–3024.
- 400 https://doi.org/10.1128/JCM.00896-13.
- 401 (20) Green, H. C.; Haugland, R. A.; Varma, M.; Millen, H. T.; Borchardt, M. A.; Field, K. G.;
- 402 Walters, W. A.; Knight, R.; Sivaganesan, M.; Kelty, C. A.; Shanks, O. C. Improved
- 403 HF183 Quantitative Real-Time PCR Assay for Characterization of Human Fecal Pollution
- 404 in Ambient Surface Water Samples. *Applied and Environmental Microbiology* **2014**, 80
- 405 (10), 3086–3094. https://doi.org/10.1128/AEM.04137-13.
- 406 (21) Kelty, C. A.; Varma, M.; Sivaganesan, M.; Haugland, R. A.; Shanks, O. C. Distribution of
- 407 Genetic Marker Concentrations for Fecal Indicator Bacteria in Sewage and Animal Feces.

- 408 *Applied and Environmental Microbiology* **2012**, 78 (12), 4225–4232.
- 409 https://doi.org/10.1128/AEM.07819-11.
- 410 (22) Whale, A. S.; De Spiegelaere, W.; Trypsteen, W.; Nour, A. A.; Bae, Y.-K.; Benes, V.;
- 411 Burke, D.; Cleveland, M.; Corbisier, P.; Devonshire, A. S.; Dong, L.; Drandi, D.; Foy, C.
- 412 A.; Garson, J. A.; He, H.-J.; Hellemans, J.; Kubista, M.; Lievens, A.; Makrigiorgos, M.
- 413 G.; Milavec, M.; Mueller, R. D.; Nolan, T.; O'Sullivan, D. M.; Pfaffl, M. W.; Rödiger, S.;
- 414 Romsos, E. L.; Shipley, G. L.; Taly, V.; Untergasser, A.; Wittwer, C. T.; Bustin, S. A.;
- 415 Vandesompele, J.; Huggett, J. F. The Digital MIQE Guidelines Update: Minimum
- 416 Information for Publication of Quantitative Digital PCR Experiments for 2020. *Clinical*
- 417 *Chemistry* **2020**, *66* (8), 1012–1029. https://doi.org/10.1093/clinchem/hvaa125.
- 418 (23) Pentinmikko, N.; Katajisto, P. The Role of Stem Cell Niche in Intestinal Aging.

419 *Mechanisms of Ageing and Development* **2020**, *191*, 111330.

- 420 https://doi.org/10.1016/j.mad.2020.111330.
- 421 (24) Liu, T. C.; Vanbuskirk, K.; Ali, S. A.; Kelly, M. P.; Holtz, L. R.; Yilmaz, O. H.; Sadiq,
- 422 K.; Iqbal, N.; Amadi, B.; Syed, S.; Ahmed, T.; Moore, S.; Ndao, I. M.; Isaacs, M. H.;
- 423 Pfeifer, J. D.; Atlas, H.; Tarr, P. I.; Denno, D. M.; Moskaluk, C. A. A Novel Histological
- 424 Index for Evaluation of Environmental Enteric Dysfunction Identifies Geographic-
- 425 Specific Features of Enteropathy among Children with Suboptimal Growth. *PLoS*
- 426 *Neglected Tropical Diseases* **2020**, *14* (1), 1–21.
- 427 https://doi.org/10.1371/journal.pntd.0007975.
- 428 (25) Brown, J.; Cumming, O. Stool-Based Pathogen Detection Offers Advantages as an
- 429 Outcome Measure for Water, Sanitation, and Hygiene Trials. *American Journal of*

- 430 *Tropical Medicine and Hygiene* 2020, *102* (2), 260–261. https://doi.org/10.4269/ajtmh.19431 0639.
- 432 (26) Baqui, A. H.; Black, R. E.; Yunus, M.; Hoque, A. R. A.; Chowdhury, H. R.; Sack, R. B.
- 433 Methodological Issues in Diarrhoeal Diseases Epidemiology: Definition of Diarrhoeal
- 434 Episodes. International Journal of Epidemiology **1991**, 20 (4), 1057–1063.
- 435 https://doi.org/10.1093/ije/20.4.1057.
- 436 (27) Arnold, B. F.; Galiani, S.; Ram, P. K.; Hubbard, A. E.; Briceño, B.; Gertler, P. J.; Colford,
- 437 J. M. Optimal Recall Period for Caregiver-Reported Illness in Risk Factor and
- 438 Intervention Studies: A Multicountry Study. American Journal of Epidemiology 2013, 177
- 439 (4), 361–370. https://doi.org/10.1093/aje/kws281.
- 440 (28) Mayer, R. E.; Reischer, G. H.; Ixenmaier, S. K.; Derx, J.; Blaschke, A. P.; Ebdon, J. E.;
- 441 Linke, R.; Egle, L.; Ahmed, W.; Blanch, A. R.; Byamukama, D.; Savill, M.; Mushi, D.;
- 442 Cristóbal, H. A.; Edge, T. A.; Schade, M. A.; Aslan, A.; Brooks, Y. M.; Sommer, R.;
- 443 Masago, Y.; Sato, M. I.; Taylor, H. D.; Rose, J. B.; Wuertz, S.; Shanks, O. C.; Piringer,
- 444 H.; Mach, R. L.; Savio, D.; Zessner, M.; Farnleitner, A. H. Global Distribution of Human-
- 445 Associated Fecal Genetic Markers in Reference Samples from Six Continents.
- 446 *Environmental Science & Technology* **2018**, *52* (9), *5076–5084*.
- 447 https://doi.org/10.1021/acs.est.7b04438.
- 448 (29) Williams, J. M.; Duckworth, C. A.; Burkitt, M. D.; Watson, A. J. M. M.; Campbell, B. J.;
- 449 Pritchard, D. M. Epithelial Cell Shedding and Barrier Function: A Matter of Life and
- 450 Death at the Small Intestinal Villus Tip. *Veterinary Pathology* **2015**, *52* (3), 445–455.
- 451 https://doi.org/10.1177/0300985814559404.

- 452 (30) Hall, P. A.; Coates, P. J.; Ansari, B.; Hopwood, D. Regulation of Cell Number in the
- 453 Mammalian Gastrointestinal Tract: The Importance of Apoptosis. J Cell Sci **1994**, 107 (
- 454 *Pt 1* (12), 3569–3577.
- 455 (31) Barkla, D. H.; Gibson, P. R. The Fate of Epithelial Cells in the Human Large Intestine.
- 456 *Pathology* **1999**, *31* (3), 230–238. https://doi.org/10.1080/003130299105043.
- 457 (32) Watson, A. J. M.; Hall, L. J.; Hughes, K. R. Cell Shedding: Old Questions Answered.
- 458 *Gastroenterology* **2012**, *143* (5), 1389–1391. https://doi.org/10.1053/j.gastro.2012.09.025.
- 459 (33) Eisenhoffer, G. T.; Loftus, P. D.; Yoshigi, M.; Otsuna, H.; Chien, C.-B.; Morcos, P. A.;
- 460 Rosenblatt, J. Crowding Induces Live Cell Extrusion to Maintain Homeostatic Cell
- 461 Numbers in Epithelia. *Nature* **2012**, *484* (7395), 546–549.
- 462 https://doi.org/10.1038/nature10999.
- 463 (34) Bullen, T. F.; Forrest, S.; Campbell, F.; Dodson, A. R.; Hershman, M. J.; Pritchard, D. M.;
- 464 Turner, J. R.; Montrose, M. H.; Watson, A. J. M. Characterization of Epithelial Cell
- 465 Shedding from Human Small Intestine. *Laboratory Investigation* **2006**, 86 (10), 1052–
- 466 1063. https://doi.org/10.1038/labinvest.3700464.
- 467 (35) Patterson, A. M.; Watson, A. J. M. Deciphering the Complex Signaling Systems That
- 468 Regulate Intestinal Epithelial Cell Death Processes and Shedding. *Frontiers in*
- 469 *Immunology* **2017**, 8 (JUL), 1–7. https://doi.org/10.3389/fimmu.2017.00841.
- 470 (36) Williams, J. M.; Duckworth, C. A.; Watson, A. J. M.; Frey, M. R.; Miguel, J. C.; Burkitt,
- 471 M. D.; Sutton, R.; Hughes, K. R.; Hall, L. J.; Caamano, J. H.; Campbell, B. J.; Pritchard,
- 472 D. M. A Mouse Model of Pathological Small Intestinal Epithelial Cell Apoptosis and
- 473 Shedding Induced by Systemic Administration of Lipopolysaccharide. Disease Models &
- 474 *Mechanisms* **2013**, *6* (6), 1388–1399. https://doi.org/10.1242/dmm.013284.

- 475 (37) Knodler, L. A.; Vallance, B. A.; Celli, J.; Winfree, S.; Hansen, B.; Montero, M.; Steele-
- 476 Mortimer, O. Dissemination of Invasive Salmonella via Bacterial-Induced Extrusion of
- 477 Mucosal Epithelia. *Proceedings of the National Academy of Sciences* **2010**, *107* (41),
- 478 17733–17738. https://doi.org/10.1073/pnas.1006098107.
- 479 (38) Boshuizen, J. A.; Reimerink, J. H. J.; Korteland-van Male, A. M.; van Ham, V. J. J.;
- 480 Koopmans, M. P. G.; Büller, H. A.; Dekker, J.; Einerhand, A. W. C. Changes in Small
- 481 Intestinal Homeostasis, Morphology, and Gene Expression during Rotavirus Infection of
- 482 InfantMice. *Journal of Virology* **2003**, 77 (24), 13005–13016.
- 483 https://doi.org/10.1128/JVI.77.24.13005-13016.2003.
- 484 (39) Ahlquist, D. A.; Harrington, J. J.; Burgart, L. J.; Roche, P. C. Morphometric Analysis of
- 485 the "Mucocellular Layer" Overlying Colorectal Cancer and Normal Mucosa: Relevance to
- 486 Exfoliation and Stool Screening. *Human Pathology* **2000**, *31* (1), 51–57.
- 487 https://doi.org/10.1016/S0046-8177(00)80198-7.
- 488 (40) Atmar, R. L.; Ramani, S.; Estes, M. K. Human Noroviruses. *Current Opinion in Infectious* 489 *Diseases* 2018, *31* (5), 422–432. https://doi.org/10.1097/QCO.00000000000476.
- 490 (41) Estes, M. K.; Ettayebi, K.; Tenge, V. R.; Murakami, K.; Karandikar, U.; Lin, S. C.; Ayyar,
- 491 B. V.; Cortes-Penfield, N. W.; Haga, K.; Neill, F. H.; Opekun, A. R.; Broughman, J. R.;
- 492 Zeng, X. L.; Blutt, S. E.; Crawford, S. E.; Ramani, S.; Graham, D. Y.; Atmar, R. L.
- 493 Human Norovirus Cultivation in Nontransformed Stem Cell-Derived Human Intestinal
- 494 Enteroid Cultures: Success and Challenges. *Viruses* **2019**, *11* (7), 9–11.
- 495 https://doi.org/10.3390/v11070638.

- 496 (42) Karst, S. M.; Tibbetts, S. A. Recent Advances in Understanding Norovirus Pathogenesis.
- 497 *Journal of Medical Virology* **2016**, 88 (11), 1837–1843.
- 498 https://doi.org/10.1002/jmv.24559.
- 499 (43) Guerrant, R. L.; Araujo, V.; Soares, E.; Kotloff, K.; Lima, A. A. M.; Cooper, W. H.; Lee,
- 500 A. G. Measurement of Fecal Lactoferrin as a Marker of Fecal Leukocytes. *Journal of*
- 501 *Clinical Microbiology* **1992**, *30* (5), 1238–1242. https://doi.org/10.1128/JCM.30.5.1238-
- 502 1242.1992.
- 503 (44) Mercado, E. H.; Ochoa, T. J.; Ecker, L.; Cabello, M.; Durand, D.; Barletta, F.; Molina,
- 504 M.; Gil, A. I.; Huicho, L.; Lanata, C. F.; Cleary, T. G. Fecal Leukocytes in Children
- 505 Infected with Diarrheagenic Escherichia Coli. *Journal of Clinical Microbiology* **2011**, 49
- 506 (4), 1376–1381. https://doi.org/10.1128/JCM.02199-10.
- 507 (45) Luissint, A. C.; Parkos, C. A.; Nusrat, A. Inflammation and the Intestinal Barrier:
- 508 Leukocyte–Epithelial Cell Interactions, Cell Junction Remodeling, and Mucosal Repair.
- 509 *Gastroenterology* **2016**, *151* (4), 616–632. https://doi.org/10.1053/j.gastro.2016.07.008.
- 510 (46) Ingelsson, B.; Söderberg, D.; Strid, T.; Söderberg, A.; Bergh, A.-C.; Loitto, V.; Lotfi, K.;
- 511 Segelmark, M.; Spyrou, G.; Rosén, A. Lymphocytes Eject Interferogenic Mitochondrial
- 512 DNA Webs in Response to CpG and Non-CpG Oligodeoxynucleotides of Class C.
- 513 *Proceedings of the National Academy of Sciences* **2018**, *115* (3), E478–E487.
- 514 https://doi.org/10.1073/pnas.1711950115.
- 515 (47) Boyapati, R. K.; Tamborska, A.; Dorward, D. A.; Ho, G.-T. Advances in the
- 516 Understanding of Mitochondrial DNA as a Pathogenic Factor in Inflammatory Diseases.
- 517 *F1000Res* **2017**, *6* (0), 169. https://doi.org/10.12688/f1000research.10397.1.

518	(48)	Colford, J. M.; Wade, T. J.; Schiff, K. C.; Wright, C. C.; Griffith, J. F.; Sandhu, S. K.;
519		Burns, S.; Sobsey, M.; Lovelace, G.; Weisberg, S. B. Water Quality Indicators and the
520		Risk of Illness at Beaches With Nonpoint Sources of Fecal Contamination. Epidemiology
521		2007, 18 (1), 27–35. https://doi.org/10.1097/01.ede.0000249425.32990.b9.
522	(49)	Dwight, R. H.; Baker, D. B.; Semenza, J. C.; Olson, B. H. Health Effects Associated with
523		Recreational Coastal Water Use: Urban Versus Rural California. American Journal of
524		Public Health 2004, 94 (4), 565–567. https://doi.org/10.2105/AJPH.94.4.565.
525	(50)	Wade, T. J.; Calderon, R. L.; Sams, E.; Beach, M.; Brenner, K. P.; Williams, A. H.;
526		Dufour, A. P. Rapidly Measured Indicators of Recreational Water Quality Are Predictive
527		of Swimming-Associated Gastrointestinal Illness. Environmental Health Perspectives
528		2006 , <i>114</i> (1), 24–28. https://doi.org/10.1289/ehp.8273.
529	(51)	Wade, T. J.; Calderon, R. L.; Brenner, K. P.; Sams, E.; Beach, M.; Haugland, R.; Wymer,
530		L.; Dufour, A. P. High Sensitivity of Children to Swimming-Associated Gastrointestinal
531		Illness. Epidemiology 2008, 19 (3), 375–383.
532		https://doi.org/10.1097/EDE.0b013e318169cc87.
533	(52)	Yau, V. M.; Schiff, K. C.; Arnold, B. F.; Griffith, J. F.; Gruber, J. S.; Wright, C. C.;
534		Wade, T. J.; Burns, S.; Hayes, J. M.; McGee, C.; Gold, M.; Cao, Y.; Boehm, A. B.;
535		Weisberg, S. B.; Colford, J. M. Effect of Submarine Groundwater Discharge on Bacterial
536		Indicators and Swimmer Health at Avalon Beach, CA, USA. Water Research 2014, 59,
537		23–36. https://doi.org/10.1016/j.watres.2014.03.050.
538	(53)	Sukhrie, F. H. A.; Teunis, P.; Vennema, H.; Copra, C.; Thijs Beersma, M. F. C.;
539		Bogerman, J.; Koopmans, M. Nosocomial Transmission of Norovirus Is Mainly Caused

- 540 by Symptomatic Cases. *Clinical Infectious Diseases* **2012**, *54* (7), 931–937.
- 541 https://doi.org/10.1093/cid/cir971.
- 542 (54) Haas, C. N. Quantitative Microbial Risk Assessment and Molecular Biology: Paths to
- 543 Integration. *Environmental Science and Technology*. American Chemical Society July 21,
- 544 2020, pp 8539–8546. https://doi.org/10.1021/acs.est.0c00664.
- 545 (55) He, X.; Chen, H.; Shi, W.; Cui, Y.; Zhang, X.-X. Persistence of Mitochondrial DNA
- Markers as Fecal Indicators in Water Environments. *Science of The Total Environment*2015, *533*, 383–390. https://doi.org/10.1016/j.scitotenv.2015.06.119.
- 548 (56) Korajkic, A.; McMinn, B.; Harwood, V. Relationships between Microbial Indicators and
- 549 Pathogens in Recreational Water Settings. International Journal of Environmental
- 550 *Research and Public Health* **2018**, *15* (12), 2842. https://doi.org/10.3390/ijerph15122842.
- 551 (57) Korajkic, A.; Wanjugi, P.; Brooks, L.; Cao, Y.; Harwood, V. J. Persistence and Decay of
- 552 Fecal Microbiota in Aquatic Habitats. *Microbiology and Molecular Biology Reviews*
- 553 **2019**, *83* (4). https://doi.org/10.1128/MMBR.00005-19.
- 554 (58) Kapoor, V.; Smith, C.; Santo Domingo, J. W.; Lu, T.; Wendell, D. Correlative Assessment
- 555 of Fecal Indicators Using Human Mitochondrial DNA as a Direct Marker. *Environmental*
- 556 *Science & Technology* **2013**, *47* (18), 130826150654007.
- 557 https://doi.org/10.1021/es4020458.
- 558 (59) Malla, B.; Haramoto, E. Host-Specific Mitochondrial DNA Markers for Tracking the
- 559 Sources of Fecal Pollution. *Current Opinion in Environmental Science and Health*.
- 560 Elsevier B.V. August 1, 2020, pp 34–46. https://doi.org/10.1016/j.coesh.2020.02.006.
- 561 (60) Tanvir Pasha, A. B. M.; Hinojosa, J.; Phan, D.; Lopez, A.; Kapoor, V. Detection of
- 562 Human Fecal Pollution in Environmental Waters Using Human Mitochondrial DNA and

563	Correlation with General and Human-Associated Fecal Genetic Markers. Journal of Water
564	and Health 2020, 18 (1), 8-18. https://doi.org/10.2166/wh.2019.197.

- 565 (61) Villemur, R.; Imbeau, M.; Vuong, M. N.; Masson, L.; Payment, P. An Environmental
- 566 Survey of Surface Waters Using Mitochondrial DNA from Human, Bovine and Porcine
- 567 Origin as Fecal Source Tracking Markers. *Water Research* **2015**, *69*, 143–153.
- 568 https://doi.org/10.1016/j.watres.2014.10.063.
- 569 (62) Zimmerman, B. D.; Ashbolt, N. J.; Garland, J. L.; Keely, S.; Wendell, D. Human
- 570 Mitochondrial DNA and Endogenous Bacterial Surrogates for Risk Assessment of
- 571 Graywater Reuse. *Environmental Science and Technology* **2014**, *48* (14), 7993–8002.
- 572 https://doi.org/10.1021/es501659r.

573

574

575 For Table of Contents Only



576